专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2008121209A1 PHOTOCATALYTIC ELECTRODE AND FUEL CELL 审中-公开
标题翻译：光电电极和燃料电池
公开(公告)号：WO2008121209A1
公开(公告)日：2008-10-09
申请号：PCT/US2008/003170
申请日：2008-03-10
申请人： FORDHAM UNIVERSITY , MCMAHON, John, J.
发明人： MCMAHON, John, J.
IPC分类号： H01M4/92 , H01M4/86
CPC分类号： H01M4/92 , H01G9/2059 , H01M4/86 , H01M2008/1095 , Y10T436/16 , Y10T436/163333
摘要： The invention provides an electrode comprising an electrically conductive material having a surface capable of producing surface enhanced Raman scattering of incident light from a complex adsorbed at the surface of the electrode, the complex including the electrically conductive material combined with a second material that is substantially reducible and not substantially oxidizable. The surface of the electrode can be microroughened. The invention also includes a method for making various embodiments of the electrode, and a method of generating electricity using the electrode. In accordance with a further aspect of the invention, a fuel cell is provided including the electrode of the invention.
摘要翻译：本发明提供了一种电极，其包括导电材料，该导电材料具有能够产生吸附在电极表面的复合物的入射光的表面增强拉曼散射的表面，该复合物包括与基本可还原的第二材料组合的导电材料并且基本上不可氧化。电极的表面可以是微硬化的。本发明还包括用于制造电极的各种实施例的方法，以及使用该电极发电的方法。根据本发明的另一方面，提供了包括本发明的电极的燃料电池。

22. 发明申请

WO1998015616A1 METHODS FOR GENERATING CYTOTOXIC T CELLS IN VITRO 审中-公开
标题翻译：在体内产生细胞毒素T细胞的方法
公开(公告)号：WO1998015616A1
公开(公告)日：1998-04-16
申请号：PCT/US1997018110
申请日：1997-10-06
申请人： FORDHAM UNIVERSITY
发明人： FORDHAM UNIVERSITY , SRIVASTAVA, Pramod, K. , BINDER, Robert , BLACHERE, Nathalie, E.
IPC分类号： C12N05/06
CPC分类号： A61K39/0011 , A61K2039/5158
摘要： The present invention provides methods for generating antigen-reative cytotoxic T cells in vitro comprising culturing immune cells and antigenic cells that have at least one MHC allele in common (and preferably, are syngeneic), in which the antigenic cells have been treated according to the methods of the invention. The antigenic cells are treated by subjecting them to osmotic shock followed by irradiation. As a result, a subset of T cells are activated and mature into antigen-reactive cytotoxic T cells. The effectiveness of the procedure may be enhanced by repeated restimulations and/or the addition of heat shock protein-peptide complexes. Methods and compositions are also disclosed for the treatment and prevention in a subject of cancer or infectious disease comprising administering to the subject matched cytotoxic T cells that are generated in vitro by the present methods.
摘要翻译：本发明提供了在体外产生抗原性细胞毒性T细胞的方法，包括培养具有至少一种共同（优选是同基因）的MHC等位基因的免疫细胞和抗原性细胞，其中抗原细胞已经根据本发明的方法。通过对抗原细胞进行渗透休克，然后照射进行处理。结果，一部分T细胞被激活并成熟为抗原反应性细胞毒性T细胞。可以通过重复的再刺激和/或加入热休克蛋白 - 肽复合物来增强该程序的有效性。还公开了用于癌症或感染性疾病的受试者的治疗和预防的方法和组合物，包括向受试者施用通过本发明方法在体外产生的匹配的细胞毒性T细胞。

23. 发明授权

EP0859631B1 TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS 失效
标题翻译：用热休克/应激蛋白治疗或预防新生儿和感染性疾病
公开(公告)号：EP0859631B1
公开(公告)日：2010-01-27
申请号：EP96931527.4
申请日：1996-09-11
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K39/385 , A61K39/12 , A61K39/02 , A61K39/00 , A61K35/12 , G01N33/53 , G01N33/555 , G01N33/567
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.

24. 发明公开

EP1001807A1 ADOPTIVE IMMUNOTHERAPY UTILIZING HEAT SHOCK/STRESS PROTEIN-PEPTIDE COMPLEXES FOR PREVENTION/TREATMENT OF CANCER OR INFECTIOUS DISEASES 失效
标题翻译：过继免疫治疗采用加热/应激蛋白肽复合物的癌症或传染病预防/治疗
公开(公告)号：EP1001807A1
公开(公告)日：2000-05-24
申请号：EP98903925.0
申请日：1998-02-03
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K39/385 , A61K39/39 , C07K1/10
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/6043 , A61K2039/622 , Y02A50/466 , Y10S530/806 , Y10S530/807 , A61K2300/00
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic noeplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96. In another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising hsp70, 50 to 5000 micrograms for hsp90, and 10 to 600 micrograms for gp96.

25. 发明公开

EP0859631A1 TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS 失效
标题翻译：治疗和传染病预防与热休克/应激蛋白肿瘤
公开(公告)号：EP0859631A1
公开(公告)日：1998-08-26
申请号：EP96931527.0
申请日：1996-09-11
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K38 , A61K31 , A61K39 , A61P31 , A61P35 , C07K14 , G01N33
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.

26. 发明公开

EP0857068A1 IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASE USING ANTIGEN-PRESENTING CELLS SENSITIZED WITH HEAT SHOCK PROTEIN-ANTIGEN COMPLEXES 失效
标题翻译：蛋白质 - - 抗原 - 复杂的癌症和传染病免疫治疗热休克致敏抗原-displaying细胞的使用
公开(公告)号：EP0857068A1
公开(公告)日：1998-08-12
申请号：EP96930819.0
申请日：1996-09-11
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K38 , A61K31 , A61K35 , A61K39 , A61P31 , A61P35
CPC分类号： A61K39/0011 , A61K38/191 , A61K38/20 , A61K38/21 , A61K2039/5154 , A61K2039/6043 , A61K2039/622 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , A61K2300/00
摘要： The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon- alpha , interferon- alpha , interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.

27. 发明申请

US20140030628A1 PHOTOCATALYTIC FUEL CELL AND ELECTRODE THEREOF 审中-公开
标题翻译：光电燃料电池及其电极
公开(公告)号：US20140030628A1
公开(公告)日：2014-01-30
申请号：US13950424
申请日：2013-07-25
申请人： Fordham University
发明人： John J. McMahon
IPC分类号： H01M4/86 , H01L29/40
CPC分类号： H01M4/8657 , H01L29/401 , H01M4/9041 , H01M4/921 , H01M4/94 , H01M8/00 , H01M14/00 , H01M2004/8689 , Y02P70/56
摘要： The invention provides a novel fuel cell, the output voltage of which is pH dependent. The fuel cell comprises a membrane electrode assembly and a light source. In accordance with one embodiment, the membrane electrode assembly includes i) an electrolyte; ii) an anode operably coupled to the electrolyte; and iii) a cathode operably coupled to the electrolyte, wherein the cathode is made from an electrically conductive material and has an unroughened surface where an adsorbate material is applied. The adsorbate material used herein comprises a material having semiconductor properties, and the combination of the electrically conductive material and the adsorbate material is photosensitive and has catalytic properties. The invention also provides a novel electrode that can be used as a cathode in a fuel cell, a novel method for making the electrode, and a novel method of generating electricity using the fuel cell and/or electrode of the invention.
摘要翻译：本发明提供了一种新颖的燃料电池，其输出电压是pH依赖性的。燃料电池包括膜电极组件和光源。根据一个实施例，膜电极组件包括i）电解质; ii）可操作地耦合到电解质的阳极; 以及iii）可操作地耦合到所述电解质的阴极，其中所述阴极由导电材料制成并且具有未被增韧的表面，其中施加了被吸附材料。本文所用的被吸附材料包括具有半导体特性的材料，并且导电材料和被吸附材料的组合是光敏的并具有催化性质。本发明还提供了可用作燃料电池中的阴极的新型电极，制造电极的新方法，以及使用本发明的燃料电池和/或电极产生电力的新方法。

28. 发明授权

US07601359B1 Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins 失效
标题翻译：用热休克/应激蛋白预防和治疗原发性和转移性肿瘤性疾病和传染病的组合物和方法
公开(公告)号：US07601359B1
公开(公告)日：2009-10-13
申请号：US09090754
申请日：1998-06-04
申请人： Pramod K. Srivastava
发明人： Pramod K. Srivastava
IPC分类号： A61K35/12 , A61K39/395
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。复合物的有效量对于包含hsp70，hsp90为50-1000微克，gp96为10-600微克的复合物为10-600微克。本发明还提供了一种在个体，优选人体内测量体内肿瘤排斥的方法，包括测量个体对肿瘤特异性的MHC I类限制性CD8 +细胞毒性T淋巴细胞的产生。还提供了纯化hsp70-肽复合物的方法。

29. 发明申请

US20030012794A1 Kits comprising heat shock protein-antigenic molecule complexes 审中-公开
标题翻译：试剂盒包含热休克蛋白 - 抗原分子复合物
公开(公告)号：US20030012794A1
公开(公告)日：2003-01-16
申请号：US10212031
申请日：2002-08-02
申请人： Fordham University
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K039/00
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. nullAntigenic moleculenull as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答的方法和组合物以及预防和治疗原发性和转移性肿瘤性疾病和感染性疾病。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

30. 发明授权

US6156302A Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes 失效
标题翻译：使用用热休克蛋白 - 表位复合物敏化的巨噬细胞的采用免疫治疗
公开(公告)号：US6156302A
公开(公告)日：2000-12-05
申请号：US107696
申请日：1998-06-30
申请人： Pramod K. Srivastava
发明人： Pramod K. Srivastava
IPC分类号： A61K38/00 , A61K31/00 , A61K35/12 , A61K38/19 , A61K39/00 , A61P31/00 , A61P35/00 , A61P35/02 , A01N63/00 , A61K39/385 , A61K45/05 , C07K14/435
CPC分类号： A61K39/0011 , A61K38/191 , A61K38/20 , A61K38/21 , A61K2039/5154 , A61K2039/6043 , A61K2039/622
摘要： The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon-.alpha., interferon-.alpha., interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
摘要翻译：本发明涉及用于增强免疫应答和用于预防和治疗感染性疾病或原发性和转移性肿瘤性疾病的方法和组合物，其基于施用热休克蛋白非特异性的巨噬细胞和/或其他抗原呈递细胞（APC）共价结合肽复合物和/或抗原成分。 APC在体外在hsp-肽复合物和/或抗原成分存在下孵育。致敏细胞用或不用细胞因子包括但不限于干扰素-α，干扰素-α，白细胞介素-2，白细胞介素-4，白细胞介素-6和肿瘤神经元因子治疗而被再灌注入患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式